Overview
- Citing the July Consumer Price Index, CMS Administrator Dr. Mehmet Oz said Sunday that prescription drug prices fell 3.1 percent year‑over‑year, the largest annual drop in 63 years.
- Oz credited Most‑Favored‑Nation pricing agreements and the February launch plus May expansion of the TrumpRx platform for the decline and said 17 drugmakers covering roughly 85 percent of the market have accepted the MFN approach.
- The administration highlighted specific patient savings, saying eligible Medicare beneficiaries can access GLP‑1 medicines for about $50 a month and that TrumpRx added more than 600 generic drugs through partners such as Cost Plus Drugs, Amazon Pharmacy, and GoodRx.
- Independent analysts note the CPI number measures what pharmacies collect at sale and excludes manufacturer rebates paid later, and they point to other factors that can lower CPI drug prices such as new generics, biosimilars, and earlier Medicare negotiation tools.
- If the administration’s attribution holds, the shift could widen immediate out‑of‑pocket savings and reduce the number of patients leaving pharmacies without medicines, while critics say full contract details and firm-by‑firm effects remain undisclosed and worth watching next.